$NEXI Digging the pivot to AIM INJ platform. Preclinical work looks promising. Watching closely for IND filing and potential breakthrough in T-cell therapies. Small position for now. an honest look at company progress: https://beyondspx.com/article/neximmune-inc-nexi-pioneering-a-novel-approach-to-immunotherapy
$NEXI NexImmune, Inc. (NASDAQ:NEXI): A Promising Biotech Poised for Transformation https://beyondspx.com/article/navigating-the-uncertainty-a-deep-dive-into-neximmune-s-nexi-resilience-and-future-prospects
$NEXI Navigating the Uncertainty: A Deep Dive into NexImmune’s (NEXI) Resilience and Future Prospects https://beyondspx.com/article/navigating-the-uncertainty-a-deep-dive-into-neximmune-s-nexi-resilience-and-future-prospects
